The Zhitong Finance App learned that Xuanzhu Bio-B (02575) rose more than 5% in the morning. As of press release, it had risen 5.42% to HK$9.915, with a turnover of HK$2,779,700.

According to the news, Xuanzhu Bio-B announced results for the six months ended June 30, 2026. The group achieved revenue of 69.4 million yuan during the period, an increase of 288.1% over the previous year. According to the announcement, the increase in revenue was mainly due to sales growth driven by the launch of new products and inclusion in the national basic medical insurance drug catalogue.

During the reporting period, the Group collaborated around the four main lines of commercialization, clinical development, early R&D and business development (BD), and overall business progress was good. On the commercialization side, the channel network and academic recognition of the three marketed products continued to improve; on the clinical side, many key research on core products reached important milestones; on the early R&D side, technology platform capabilities continued to expand, and several new projects were completed; and on the BD side, external licensing and licensing were introduced in both directions, making substantial breakthroughs in the global layout.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.